<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153167">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02062190</url>
  </required_header>
  <id_info>
    <org_study_id>RESV-110553</org_study_id>
    <secondary_id>ufrgs110553</secondary_id>
    <nct_id>NCT02062190</nct_id>
  </id_info>
  <brief_title>Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia</brief_title>
  <official_title>Effects of Reveratrol on Cardiovascular Risk Markers and Cognitive Performance in Patients With Schizophrenia: a Randomized Clinical Trilal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Rio Grande do Sul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Rio Grande do Sul</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resveratrol supplementation may improve cardiovascular risk factors and cognitive parameters
      in patients with schizophrenia taking antipsychotics?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo-controlled trial comparing supplementation with
      resveratrol or placebo in patients diagnosed with schizophrenia.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Assessment of cardiovascular risk will be realized by measurement of cytokine levels, C-reactive protein and cholesterol levels.</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of cardiovascular risk will be realized by measurement of cytokine levels (IL-12p70, IL-6, IL-10, IL-1b, IL-8 and TNF-α), C-reactive protein and cholesterol levels (total cholesterol, LDL, HDL, triglycerides) in patients with schizophrenia before and after supplementation with resveratrol or placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive performance will be assessed with a battery of cognitive tests and BPRS  (brief psychiatric rating scale) to assess symptoms.</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cognitive performance will be assessed with a battery of cognitive tests (Hopkins, for verbal memory; Stroop: for executive function; Digits WAIS-III, for attention; and Sequence numbers and letters for verbal memory and attention) and BPRS  (brief psychiatric rating scale) to assess symptoms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Nutritional evaluation will be conducted by anthropometric data and food intake by 24-hour Recall Survey.</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Nutritional evaluation will be conducted by anthropometric data (weight, height, waist and hip circumference, body fat percentage) and food intake by 24-hour Recall Survey (24HR).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>resveratrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>corn starch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(10 patients) 100mg 2x/day
1 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>resveratrol</intervention_name>
    <description>100mg 2x/day
1 month</description>
    <arm_group_label>resveratrol</arm_group_label>
    <other_name>Resveratrol (10 patients)</other_name>
    <other_name>Placebo (10 patients)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men 18-65 years old, diagnosed with schizophrenia according to DSM-IV and ICD-10, which
        are in clozapine medication for at least 6 months.

        Exclusion Criteria:

        Patients will be excluded from the study:

          -  Have a diagnosis of diabetes

          -  Use other antipsychotic drugs, clozapine beyond

          -  Using medicines for diabetes or dyslipidaemia

          -  Accept not participate in any stage of the research.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karine Zortéa</last_name>
    <email>karine.persobnaldiet@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HCPA</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karine Zortéa, MD</last_name>
      <phone>84296901</phone>
      <email>karine.personaldiet@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Karine Zortéa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Rio Grande do Sul</investigator_affiliation>
    <investigator_full_name>Karine Zortéa</investigator_full_name>
    <investigator_title>Master</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
